Trial Profile

Dual Thrombolytic Therapy With Mutant Pro-urokinase (M-pro-urokinase, HisproUK) and Low Dose Alteplase for Ischemic Stroke

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 01 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs TS 01 (Primary) ; Alteplase
Indications Stroke
Focus Adverse reactions
Acronyms DUMAS

Most Recent Events

24 Sep 2024 According to Thrombolytic Science media release, following promising Phase II results from the DUMAS trial in stroke patients in the Netherlands, we are now advancing to a Phase II trial in the UK for myocardial infarction following MHRA approval.
05 Sep 2023 Status changed from recruiting to completed.
22 May 2023 Results(n=238) assessing Safety and Efficacy of Dual Thrombolytic Therapy With Mutant Prourokinase and Small Bolus Alteplase for Ischemic Stroke published in the JAMA Neurology

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com